Safety and effectiveness of low-protein diet supplemented with ketoacids in diabetic patients with chronic kidney disease

Vincenzo Bellizzi1*, Patrizia Calella2, Julia Nava Hernández2, Verónica Figueroa González3, Silvia Moran Lira3, Serena Torraca1, Rocio Urbina Arronte3, Pietro Cirillo4, Roberto Minutolo5 and Rafael A. Montúfar Cárdenas3

Abstract

Background: The impact of the low-protein diet on nutrition in CKD diabetics is uncertain.

Methods: The metabolic and nutritional effects of a low-protein (0.5–0.6 g/kg/d), normal-high energy (30–35 kcal/kg/d) diet supplemented with ketoacids (LPD-KA) were prospectively evaluated in CKD patients with (DM) and without (non-DM) diabetes mellitus.

Results: 197 patients on CKD stages 3–5 were enrolled. DM (n = 81) and non-DM (n = 116) were comparable for gender (Male 58 vs 55%), age (66 ± 9 vs 63 ± 18 years), renal function (eGFR 23 ± 13 vs 24 ± 13 mL/min). After 6-month, serum urea (DM: 131 ± 58 to 105 ± 49 mg/dl, p < 0.05; non-DM: 115 ± 52 to 88 ± 36, p < 0.05) and phosphate (DM: 4.5 ± 1.3 to 4.1 ± 1.2 mg/dl, p = 0.06; non-DM: 4.3 ± 1.0 to 3.7 ± 0.8, p < 0.05) declined. Fasting glucose decreased in DM (126 ± 52 to 103 ± 29 mg/dl, p < 0.05) without insulin dose increase. These effects were preserved after 3-year. Serum albumin did not change after 6 months (DM: 3.7 ± 0.6 to 3.8 ± 0.4 mg/dl; non-DM: 4.0 ± 0.6 to 4.0 ± 0.4) and in the long-term. Body weight (BW) declined after the diet start (DM: 68.9 ± 14.3 to 65.1 ± 12.1 kg, p < 0.05; non-DM: 66.6 ± 15.1 to 64.1 ± 15.1, p < 0.05) and was stable at 6 months and 3 years. Muscle strength at baseline was reduced in all patients and remained stable during the diet period. Changes of nutritional markers during the study were similar among groups and diabetes was not associated to any nutritional change at the multivariate analysis. As attain wasting, lower BMI (< 23 kg/m2) and albumin (< 3.8 g/dl) levels were present in 1/3 patients at start and along 3 years, cholesterol never dropped below the lower threshold (< 100 mg/dl) and poorer FM (< 10%) was less than 10% during the study in both groups.

Conclusions: In diabetic CKD patients a low-protein diet supplemented with ketoacids improves uremia and diabetes, causes sudden decline of body weight which remains stable over time and has not a negative effect on wasting and muscle mass and fitness. In diabetic CKD patients the LPD-KA is safe and the nutritional impact is the same as in non-diabetics CKD.

Keywords: Low-protein diet, Ketoacids, CKD, Diabetes, Protein-energy wasting, Insulin resistance
Background
During the last decades the prevalence of chronic kidney disease (CKD) increased worldwide, the end-stage renal disease (ESRD) has become one of the major causes of mortality in the world and the use of renal replacement therapy is projected to double by 2030 [1, 2]. Additionally, it emerged that dialysis is not capable to prolong life while, in contrast, reduces the quality of the life and the individual functional capacity in most patients [3]. Therefore, in addition to a population-based strategies to prevent ESRD, an efficacious conservative treatment for non-dialysis CKD patients is mandatory. The nutritional treatment is a main part of the conservative treatment for non-dialysis CKD, aiming to reduce the metabolic disturbance of CKD, the signs and symptoms of uremia and the progression of renal disease and may delay dialysis [4]. Consequently, the low-protein diet, which is the cornerstone of the nutritional treatment for CKD, plays a central role in the conservative management of CKD [5].

A major possible drawback which has been related to the use of the low-protein diet in CKD is the risk of protein-energy wasting (PEW) that is the loss of body store of proteins and energy reserves. The cause of PEW in renal patients is multifactorial and a reduced nutrient intakes may contribute to the syndrome in addition to several conditions such as inflammation or resistance to insulin which play a crucial role in the loss of muscle mass [6]. The most risky nutrient deprivation for CKD patients is the energy intake, rather than the protein intake [7]. Indeed, PEW is very rare in CKD patients on regular low-protein diet if adequate energy intake is observed and when the dietary regimen goes on under a regular counselling and a close nutritional monitoring [8–10]. Among the low-protein diets for CKD, there is a very restricted one which is supplemented with aminoacids and ketoacids (LPD-KA) in order to cover the minimum body nitrogen need and to minimize the nitrogen load. The LPD-KA has been proven to achieve a more rigorous metabolic control, a reduction of the cardiovascular risk factors related to advanced CKD and to further slow-down the CKD progression delaying the start of dialysis [11, 12]. In contrast, a very restricted renal diet may expose the CKD patient to higher risk of insufficient nutrient intake and of PEW. A regular clinical follow-up and a strict dietitian assistance, however, allows to maintain of a good nutritional status with such LPD-KA, even in elderly patients [13].

Diabetes mellitus (DM) is rapidly increasing all over the world and diabetic nephropathy is estimated to develop in four out of ten DM patients, representing the main cause of CKD; indeed, around one over three CKD patients is affected by diabetes [14]. Therefore, a low-protein diet supplemented with ketoacids could be a resource for diabetic CKD patients, but these subjects are more inflamed, resistant to insulin, comorbid, hypercatabolic and, at least in theory, they might require more proteins and aminoacids to compensate the catabolic status [15]. Hence, a restricted diet such as the low-protein diet – LPD may not provide sufficient amounts of nutrients and energy and, as a result, could increase the risk of PEW. Furthermore, because of the reduced energy amount resulting from the lower protein intake, the LPD contains more carbohydrates to reach the energy request and the high carbohydrates can worsen the control of diabetes. Safety data on the relation between long-term use of protein restriction and PEW in diabetic CKD are scarce. This observational, prospective study aimed at evaluating the effects of a LPD supplemented with ketoacids on long-term nutritional outcome in diabetic CKD patients.

Methods
Patients and groups
This is a observational, prospective study conducted in the renal clinic of the Centro de Atención Nutricional Fresenius Kabi in México City, Mexico. Consecutive outpatients with non-dialysis chronic kidney disease (CKD) on regular nephrology and nutritional follow-up were enrolled in the period between January 1st 2010 and August 1st 2013; the end of follow-up was on August 31st 2015. The research protocol involving these patients was approved by the local ethical committee, the “Comité Local de Investigación y Ética del Hospital de Especialidades Centro Médico Nacional la Raza del Instituto Mexicano del Seguro Social”, and all subjects enrolled into the study gave their informed consent to participate to the research.

Selection criteria were: a) age ≥ 18 years; b) CKD stage 3 or higher by estimated GFR; c) follow-up of at least 6 months in CKD clinic; d) stable renal function (variation of eGFR < 30% in the last 3 months). Exclusion criteria were: a) previous consumption of LPD-KA; b) history of dialysis or renal transplantation; c) current treatment with immunosuppressive drugs; d) pregnancy or lactation; e) malignancy; f) congestive heart failure (NYHA class III-IV); g) severe undernutrition (body mass index – BMI < 20 kg/m² and serum albumin < 3.0 g/dl, or BMI < 17.5 kg/m² irrespective of the albumin value, or unintentional body weight – BW reduction > 7.5% in the last 3 months); h) inability of spontaneous feeding; i) any acute illness during the previous 3 months.

Design of the Study and Nutritional Treatment
Selected patients were monitored for a run-in period prior to the final enrolment. If the inclusion criteria were confirmed, patients underwent a dietitian evaluation and were
prescribed a low-protein diet supplemented with ketoacids (LPD-KA), containing 0.5–0.6 g proteins/kg iBW/day, low amount of purines, sodium (<2 g/day) and phosphorus (<800 mg/day) and normal-high amount of energy (30–35 kcal/kg iBW/day). The diet was supplemented with a mixture of aminoacids and ketoacids (Ketosteril®, Fresenius Kabi, 1 tab/ 5–7 kg BW/day) and omega-3 fatty acids (3 g/day) were recommended.

The dietary plan was explained to patients during a nutritional consultation, using several educational tools like examples of different kind of meals, recipes and food models. In addition, a list of food equivalents in which foods are grouped by the content of proteins, potassium and energy, according to the Mexican Food Equivalent System – MFES [16], was provided to patients. The nutritional treatment was under the supervision and the continuous support of dietitians and each patient has been guided to create his own menu.

The study lasted at least 6 months; all patients along this period were evaluated at baseline, and after the start of the diet at 1, 2 and 6 month-time (short-term observation). At this point, patients were asked to continue the diet for at least two years, with further clinical evaluations every 6 months (long-term observation). At each visit, blood samples were collected to determine the laboratory data and clinical and nutritional evaluations were performed by a nephrologist and a dietitian. The outcome of the study was the nutritional status.

Measurements and calculations
In the morning, after a fasting period of 10 to 12 h, patients underwent blood sampling. Serum creatinine, electrolytes, glucose, urea, uric acid, haemoglobin, proteins, albumin and lipids were analysed by standard methods. Renal function was estimated with the GFR calculated by the CKD-EPI equation and the CKD stages were defined according to KDIGO guidelines [17, 18].

At each visit, a clinical evaluation, including body composition and muscle strength measurements, was done. Body weight was measured to the nearest 0.1 kg and height to the nearest 0.5 cm. BMI was calculated as the ratio weight/height² (kg/m²). Waist and hip circumferences were also measured and the W/H ratio was calculated.

The body composition was estimated by bioimpedance analysis – BIA, using a multi-frequency Body Composition Analyzer (PLUSAVIS 333; frequencies range: 5–50-250 kHz; Jawon medical Co. Ltd.; Korea). The measures were taken with patient wearing only a gown. The electrodes were placed on the feet and both hands. The subject had to be in the post-absorptive state and was placed in standardized conditions: quiet environment, ambient temperature of 22–24 °C [19, 20]. The evaluated BIA derived variables were total body water (TBW) and fat-free mass (FFM); fat mass (FM) was calculated as the difference between BW and FFM.

The muscle strength was measured by a digital hand grip dynamometer (T.K.K. 540.1 GRIP D; Takei Scientific Instruments Co. Ltd.; Niigata, Japan). The measures were taken on the dominant hand. The patient was standing upright; he/she was asked to hold the device with the grip meter indicator facing outward, to leave the arm down naturally and finally to clasp the grip with full force for 3 s. Three measures were taken within a half-minute of each other and the mean value was reported.

Statistics
Statistical analyses were performed using the statistical software SPSS version 22 (IBM SPSS Statistics). Continuous variables were expressed as mean ± standard deviation (SD) and categorical variables were expressed as percent. During the analysis, the patients were grouped in diabetics (DM) and without diabetes (non-DM). Comparison of all parameters at baseline and at the end of follow-up periods and comparison of parameters changes during the study between groups were performed by unpaired Student t-test. Comparison within group was made by paired Student t-test, ANOVA or chi-square-test as appropriate. To verify if diabetes was associated with changes during the long-term study of main clinical and nutritional parameters (body weight, blood pressure, muscle strength, serum levels of urea, uric acid, phosphates and albumin), we performed multiple regression analyses. For each parameter separately, we built a multivariable model including the variation during the follow-up (final-basal delta) adjusted for the same parameter at baseline, diabetes and potential confounders, i.e. the individual characteristics differing between groups at baseline (gender, age and eGFR). A two-tail P value < 0.05 was considered statistically significant.

Results
Patients
Among the screened patients, those who refused the nutritional treatment or declared they cannot be adherent to the LPD or did not meet the inclusion criteria were excluded; these patients were not submitted to any further evaluation.

Two hundred nine patients were selected on the basis of the initial inclusion criteria; after the run-in period, 197 patients (DM = 81; non-DM = 116) were enrolled into the study, starting the low-protein diet supplemented with ketoacids – LPD-KA. All patients completed the 6 months diet period (short-term observation). Afterwards, 86 patients did not continue the LPD-KA; among the remaining 111 patients who continued the diet, 47 did not reach a minimum follow-up of 24 months at the end of the study. In summary, 64 patients (DM = 29; non-DM = 35)
remained on the LPD-KA for 2 years or more, with a mean follow-up of 38 months (long-term observation).

**Short-term observation**

In the enrolled patients the mean age was 64 years and males were 57%. Renal diseases was type-1 = 6% and type-2 = 94% in diabetes mellitus (DM) and hypertension = 59%, glomerular nephritis = 3%, interstitial nephritis = 8%, other/unknown = 31% in non-DM groups. The mean renal function measured by eGFR was 23.5 ml/min with 25, 43 and 32% of patients in CKD stages 3, 4 and 5, respectively. Excretion measured by eGFR was 23,5 ml/min with 25, 43 and 30% in non-DM groups. The mean renal function measured by eGFR was 23.5 ml/min with 25, 43 and 32% of patients in CKD stages 3, 4 and 5, respectively. Except for renal disease, there were no differences between groups (Table 1). The patients excluded from the study after the run-in period had similar characteristics.

Dietary treatment produced several significant metabolic changes in all patients (Table 2). As expected, serum urea, which was a little different among groups at baseline (p < 0.05), significantly decreased by the same extent (p < 0.05) in both DM and non-DM. Uric acid level decreased in all patients, but significantly only in non-DM (p < 0.05), with a final similar level between groups. Serum phosphate decreased in non-DM (p < 0.05), with a final lower level as compared to DM (p < 0.05). The fasting glucose in DM was always significantly higher versus non-DM (p < 0.05) and significantly declined in DM (p < 0.05), with no increase in the prescription of insulin dose.

Table 1 Individual characteristics of CKD patients on low-protein diet and ketoacids followed in the short-term (6 months)

|                        | Total     | Diabetes | non-DM    |
|------------------------|-----------|----------|-----------|
| **N**                  | 197       | 81       | 116       |
| **Age, years**         | 64.1 ± 15.3 | 65.7 ± 9.3 | 62.9 ± 18.3 |
| **Gender, %M**         | 57        | 58       | 55        |
| **Height, m**          | 1.60 ± 0.10 | 1.60 ± 0.09 | 1.59 ± 0.10 |
| **Renal disease, %**   |           |          |          |
| Diabetes type 1        | 2.5       | 6.2*     | –         |
| Diabetes type 2        | 38.6      | 93.8*    | –         |
| Hypertension           | 34.5      | –        | 58.6      |
| Glomerular nephritis   | 1.5       | –        | 2.6       |
| Interstitial Tubular Nephritis | 4.6 | – | 7.8 |
| Other disease          | 7.1       | –        | 12.0      |
| Unknown                | 11.2      | –        | 19.0      |
| **sCreatinine, mg/dl** | 3.38 ± 1.84 | 3.57 ± 2.09 | 3.25 ± 1.64 |
| **eGFR, ml/min**       | 23.5 ± 12.9 | 22.7 ± 13.0 | 24.01 ± 13.0 |
| **CKD stage, %**       |           |          |          |
| 3                      | 25.0      | 24.7     | 25.2      |
| 4                      | 43.4      | 39.5     | 46.1      |
| 5                      | 31.6      | 35.8     | 28.7      |
| **Ketoacids dose, pill/day** | 8.4 ± 2.8 | 8.8 ± 2.8 | 8.1 ± 2.8 |

*non-DM non Diabetes Mellitus, s serum, eGFR estimated glomerular filtration rate, CKD chronic kidney disease
* p < 0.05 vs. non-DM

**Table 2 Clinical and laboratory follow-up of CKD patients on low-protein diet and ketoacids followed in the short-term (6 months)**

|                      | Diabetes (n = 81) | non-DM (n = 116) |
|----------------------|------------------|-----------------|
| **SBP, mmHg**        | 137 ± 20         | 130 ± 21        |
| **DBP, mmHg**        | 78 ± 18          | 74 ± 9          |
| **Urea, mg/dl**      | 131 ± 58*        | 105 ± 49*       |
| **Uric Acid, mg/dl** | 7.0 ± 2.1        | 6.4 ± 1.8       |
| **Glucose, mg/dl**   | 126 ± 52*        | 103 ± 29*       |
| **Sodium, mEq/dl**   | 139 ± 4          | 140 ± 4         |
| **Potassium, mEq/dl**| 5.0 ± 0.8        | 4.7 ± 0.6       |
| **Calcium, mg/dl**   | 9.1 ± 0.8        | 9.1 ± 0.6       |
| **Phosphate, mg/dl** | 4.5 ± 1.3        | 4.1 ± 1.2*      |
| **Hemoglobin, g/dl** | 12.0 ± 1.7       | 11.7 ± 1.5      |
| **Total proteins, g/dl** | 6.7 ± 0.7 | 6.8 ± 0.5  |

* p < 0.05 vs. basal; ^p = 0.06 vs. basal; ^p = 0.05 vs. non-DM
Long-term observation

64 patients (DM = 29; non-DM = 35) on LPD-KA were studied for a period longer than 2 years (38 ± 13 months). Diabetic group was a little older and had a slight lower renal function with more patients in CKD stage 5; these differences, however, were not significant (Table 4).

During the long-term follow-up the LPD-KA had similar metabolic effects than in the short term (Table 5). Of relevance, serum urea and phosphates decreased ($p < 0.05$) only in DM were the basal levels were higher. Uric acid markedly decreased only in DM ($p < 0.05$). Also during the long-term the fasting glucose significantly decreased in DM ($p < 0.05$).

The same effects on the nutritional status were maintained also during the long-term LPD-KA. Albumins was almost normal and stable (Table 6). Body weight (Fig. 2) significantly ($p < 0.05$) decreased at start and then remained stable along the follow-up, with the same trend than in the short term; the body weight decline

---

**Table 3** Nutritional follow-up of CKD patients on low-protein diet and ketoacids followed in the short-term (6 months)

|                | Diabetes (n = 81) | non-DM (n = 116) |
|----------------|-------------------|------------------|
|                | basal             | final            | basal             | final             |
| BMI, kg/m²     | 26.7 ± 5.8        | 24.2 ± 6.4       | 26.0 ± 4.5        | 25.0 ± 4.9        |
| Albumin, g/dl  | 3.7 ± 0.6         | 3.8 ± 0.4        | 4.0 ± 0.6         | 4.0 ± 0.4         |
| Cholesterol, mg/dl | 186 ± 50      | 165 ± 37        | 177 ± 47          | 166 ± 38          |
| Tryglicerides, mg/dl | 183 ± 86       | 167 ± 83        | 171 ± 88          | 165 ± 78          |
| Lymphocytes, n | 2.304 ± 2.263*   | 1.640 ± 523*    | 2.210 ± 2.605     | 1.782 ± 753       |
| W/H ratio      | 0.91 ± 0.08      | 0.89 ± 0.08     | 0.92 ± 0.08       | 0.91 ± 0.08*      |
| TBW, Liters    | 36.0 ± 7.4        | 35.4 ± 7.6      | 33.8 ± 8.0        | 32.7 ± 8.1*       |
| TBW, %bw       | 50 ± 13           | 53 ± 10         | 51 ± 8            | 51 ± 6            |
| FM, Kg         | 18.6 ± 8.5        | 16.6 ± 7.1*     | 19.4 ± 7.4        | 18.4 ± 6.8*       |
| FM, % bw       | 27 ± 9            | 25 ± 9*         | 29 ± 8            | 29 ± 7            |
| FFM, Kg        | 49.9 ± 10.2       | 48.9 ± 9.9      | 47.1 ± 11.0       | 45.5 ± 11.3*      |
| FFM, %bw       | 73 ± 9            | 75 ± 9*         | 71 ± 8            | 71 ± 7            |
| BMR, Kcal      | 1.167 ± 167       | 1.171 ± 163*    | 1.159 ± 209       | 1.092 ± 195*      |
| Muscle strength, kg | 21.7 ± 8.1      | 23.9 ± 7.5*     | 24.8 ± 8.7        | 23.9 ± 7.9        |
| Male           | 25.4 ± 7.6*       | 27.7 ± 5.4      | 29.2 ± 8.2        | 27.7 ± 7.8        |
| Female         | 15.9 ± 5.6        | 16.9 ± 5.2      | 19.0 ± 5.3        | 20.0 ± 5.9        |

Muscle strength changes, $\Delta$

|                |                  |                  |
|----------------|------------------|------------------|
|                | −22 ± 3.3        | −0.9 ± 4.1       |

**Fig. 1** Body weight changes in CKD patients on low-protein diet and ketoacids during a short-term period (6 months); = Diabetes Mellitus; ----- = non Diabetes Mellitus
was associated with absolute fat mass slight reduction (DM: NS; non-DM: \( p < 0.05 \)) as in the short observation. Fat free mass was unchanged.

During the long-term LPD-KA diet, muscle strength was similar to the short-term observation, with lower prevalence of low fat mass (<10% Body Weight) was very low at baseline and was stable in DM and non-DM groups and gender sub-groups; along the long-term follow-up hand grip remained substantially unchanged (Table 6). Overall, at baseline muscle strength was under the threshold for sarcopenia [21] in 83 and 69% DM and non-DM patients, respectively; during the study it slightly improved, being respectively 79 and 54% at the final observation.

The percent changes from baseline of the clinical and nutritional parameters during the long-term follow-up were not different among groups: body weight: −3.9 ± 7.6 vs. -4.4 ± 8.5%; blood pressure: -2.1 ± 15.3 vs. -0.2 ± 12.2; muscle strength: 4.8 ± 20.0 vs. 3.9 ± 18.5; urea: -2.8 ± 58.5 vs. -1.8 ± 40.0; uric acid: −11.0 ± 35.7 vs. -6.1 ± 55.8; phosphates: −7.7 ± 18.5 vs. -3.3 ± 19.8; albumin: 1.9 ± 13.4 vs. -2.0 ± 10.7; respectively for DM and non-DM (all \( p = \text{NS} \)).

Multiple regression analyses disclosed that gender, age eGFR and diabetes did not predict the changes of nutritional and clinical parameters during the study. Indeed, diabetic status was not significantly associated with changes of body weight (\( P = 0.636 \)), blood pressure (\( P = 0.291 \)), muscle strength (\( P = 0.416 \)) and serum levels of urea (\( P = 0.273 \)), uric acid (\( P = 0.229 \)), phosphates (\( P = 0.568 \)) and albumin (\( P = 0.243 \)).

**Protein-energy wasting**

Adherence to diet prescription is usually low in the clinical practice [22]. Indirect data strongly suggest that in this study the dietary intakes were adequate and, specifically, the protein intake lowered, as testified by the reduced serum urea levels, and the energy intake remained constant, as the body weight was unchanged along the long-term follow-up.

To obtain a comprehensive evaluation of protein-energy wasting, we applied the integrated algorithm proposed by the International Society of Renal Nutrition and Metabolism which includes four different categories of nutritional criteria with the aim to early identify the nutritional risk and make timely diagnosis of PEW in CKD (Table 7) [6]. The prevalence of both low BMI (<23 kg/m²) and reduced serum albumin (<3.8 g/dl) was around one over three patients in both groups at baseline and it was similar along the study for both parameters. Low serum cholesterol (<100 mg/dl) was virtually absent along the entire study period. The prevalence of low fat mass (<10% Body Weight) was very low at baseline and was stable in DM and non-DM groups during the study.

**Discussion**

This study provides evidence that the low-protein diet supplemented with ketoacids in CKD patients with diabetes is nutritionally safe. In a cohort of well-nourished, adult outpatients with moderate to advanced CKD on regular nephrology care, a low-protein diet improved the

---

### Table 4 Basal characteristics of CKD patients on low-protein diet and ketoacids followed in the long-term (at least 2 years)

|                        | Total | Diabetes | non-DM |
|------------------------|-------|----------|--------|
| N                      | 64    | 29       | 35     |
| Age, years             | 65.8 ± 14.7 | 68.6 ± 7.6 | 63.5 ± 18.4 |
| Gender, f&M            | 68.8  | 65.5     | 71.4   |
| Height, mt             | 1.60 ± 0.09 | 1.60 ± 0.09 | 1.59 ± 0.09 |
| Renal disease, %       |       |          |        |
| Diabetes type 1        | 1.6   | 3.4\(^a\) | -      |
| Diabetes type 2        | 43.8  | 96.6\(^a\) | -      |
| Hypertension           | 40.6  | -        | 74.3   |
| Glomerular nephritis   | 1.6   | -        | 2.9    |
| Tubulo-interstitial nephritis | 4.7 | - | 8.6 |
| Other disease          | 1.6   | -        | 2.9    |
| Unknown                | 6.3   | -        | 11.4   |
| sCreatinine, mg/dl     | 3.02 ± 1.51 | 3.43 ± 1.90 | 2.68 ± 1.00 |
| eGFR, ml/min           | 25.8 ± 12.7 | 23.3 ± 12.7 | 27.9 ± 12.4 |
| CKD stage, %           |       |          |        |
| 3                      | 31.2  | 24.1     | 37.1   |
| 4                      | 46.9  | 44.8     | 48.6   |
| 5                      | 21.9  | 31       | 14.3   |
| Ketoacids dose, pill/day | 8.3 ± 2.7 | 8.6 ± 2.8 | 8.1 ± 2.6 |
| Ketoacids duration, months | 37.7 ± 13.4 | 34.8 ± 12.8 | 40.0 ± 13.7 |

**Table 5 Clinical and laboratory follow-up of CKD patients on low-protein diet and ketoacids followed in the long-term (at least 2 years)**

|                        | Diabetes | non-DM |
|------------------------|----------|--------|
| SBP, mmHg              | 140 ± 23\(^a\) | 135 ± 20\(^a\) | 128 ± 17 | 127 ± 13 |
| DBP, mmHg              | 78 ± 14  | 75 ± 11 | 73 ± 10 | 76 ± 10 |
| Urea, mg/dl            | 130 ± 64\(^a\) | 108 ± 51\(^a\) | 98 ± 48 | 90 ± 52 |
| Uric Acid, mg/dl       | 7.0 ± 1.7 | 5.8 ± 1.7\(^a\) | 6.6 ± 2.0 | 6.3 ± 1.7 |
| Glucose, mg/dl         | 114 ± 55 | 104 ± 18\(^a\) | 99 ± 16 | 94 ± 15 |
| Phosphate, mg/dl       | 4.3 ± 0.8 | 3.8 ± 0.5\(^a\) | 3.8 ± 0.8 | 3.6 ± 0.7 |
| Hemoglobin, g/dl       | 12.1 ± 1.9 | 12.1 ± 2.2 | 13.0 ± 2.3 | 13.0 ± 2.0 |
| Total proteins, g/dl   | 7.0 ± 0.6 | 7.1 ± 0.7\(^a\) | 7.1 ± 0.6 | 6.7 ± 0.5\(^a\) |

\(^{a}\)p < 0.05 vs. basal; \(^{b}\)p < 0.05 vs. non-DM
metabolic control of uremia and diabetes. Body weight declined soon after starting the low-protein diet intervention but subsequently it remained stable along time and, importantly, muscle fitness was stable or even improved over time; no further nutritional abnormalities or body composition changes were observed and no differences between diabetics and non-diabetics occurred. Overall, in diabetic patients with CKD a low-protein diet supplemented with ketoacids improves the broad metabolic profile and does not worsen nutritional status and body composition.

The cohort in this study had similar characteristics to general CKD population [23], and diabetic and non-diabetic patients were comparable for individual, renal and nutritional characteristics, though diabetics were heavier and had a slightly reduced muscle strength at baseline. As expected by reducing protein intake in CKD, after the initiation of the low-protein diet the serum levels of urea and phosphate lowered in all patients. In diabetic subjects also fasting glucose declined soon after the start of the low-protein diet and persisted close to normal levels during the long-term follow-up on LPD-KA; no information on glycated haemoglobin is available in this study. Glucose homeostasis in CKD diabetic patients during low-protein diet has never been systematically explored and few prospective data on glycaemic control during LPDs are known. In a small prospective trial, sixty-nine diabetic patients with CKD

### Table 6 Nutritional follow-up of CKD patients on low-protein diet and ketoacids followed in the long-term (at least 2 years)

|                        | Diabetes (n = 29) | non-DM (n = 35) |
|------------------------|------------------|-----------------|
| BMI, kg/m²              | 25.5 ± 3.3       | 24.3 ± 2.5     |
|                        |                  | 25.6 ± 3.8     |
|                        |                  | 24.3 ± 2.9     |
| Albumin, g/dl          | 3.8 ± 0.5        | 3.9 ± 0.4      |
|                        |                  | 4.0 ± 0.4      |
|                        |                  | 3.9 ± 0.5      |
| Cholesterol, mg/dl     | 173 ± 34         | 164 ± 23     |
|                        |                  | 170 ± 51      |
|                        |                  | 165 ± 33      |
| Tryglicerides, mg/dl   | 168 ± 85         | 147 ± 52      |
|                        |                  | 176 ± 95      |
|                        |                  | 155 ± 85      |
| W/H ratio              | 0.90 ± 0.08      | 0.90 ± 0.07    |
|                        |                  | 0.93 ± 0.09    |
|                        |                  | 0.92 ± 0.09    |
| FM, Kg                 | 17.6 ± 6.4       | 15.9 ± 6.0    |
|                        |                  | 18.4 ± 6.2    |
|                        |                  | 16.5 ± 4.9    |
| FM, % bw               | 27 ± 9           | 26 ± 9        |
|                        |                  | 28 ± 8        |
|                        |                  | 27 ± 8        |
| FFM, Kg                | 47.9 ± 9.8       | 46.5 ± 9.7    |
|                        |                  | 47.2 ± 11.9   |
|                        |                  | 45.7 ± 10.1   |
| FFM, % bw              | 73 ± 8           | 74 ± 11       |
|                        |                  | 72 ± 7        |
|                        |                  | 72 ± 7        |
| Muscle strength, kg    | 20.8 ± 7.9       | 21.2 ± 7.2    |
|                        |                  | 25.0 ± 7.8    |
|                        |                  | 25.5 ± 7.8    |
| Male                   | 24.3 ± 7.3       | 24.1 ± 6.9    |
|                        |                  | 27.8 ± 6.9    |
|                        |                  | 28.3 ± 7.1    |
| Female                 | 14.1 ± 3.3       | 15.6 ± 3.4    |
|                        |                  | 18.2 ± 5.5    |
|                        |                  | 18.6 ± 4.8    |
| Muscle strength changes, Δ | –                | 0.3 ± 3.2    |
|                        |                  | –             |
|                        |                  | 0.5 ± 3.6    |

non-DM non Diabetes Mellitus, BMI body mass index, W/H waist/hip ratio, FM fat mass, FFM fat free mass

*p < 0.05 vs. basal; †p < 0.05 vs. non-DM; ‡p = 0.06 vs. non-DM

Fig. 2 Body weight changes in CKD patients on low-protein diet and ketoacids during a long-term period (3 years); ----- = Diabetes Mellitus; —— = non Diabetes Mellitus
stage 3–4, were randomized to receive a low-protein diet or a free diet; during one year of follow-up on LPD, the serum glucose level was unchanged, but the levels of glycated haemoglobin decreased [24]. Glycated haemoglobin decreased also during a low-protein diet in a RCT in eighty-two patients with progressive CKD and type-I diabetes [25]. A systematic review and meta-analysis of randomised controlled trials evaluating the effect of low-protein diet on outcomes in patients with diabetic nephropathy showed a slight but significant decrease of glycated haemoglobin while on a low-protein diet [26]. In these latter studies a low-protein diet was prescribed but not ketoacids.

The low-protein diet has a higher content of carbohydrates to counterbalance the lower energy amount resulting from the reduced dietary protein content and to reach adequate energy intake [4]. Furthermore, the glucose metabolism in CKD is impaired because of reduced insulin sensitivity [27]. Hence, the higher dietary carbohydrates and the glucose homeostasis deficiency together may lead to the worsening of diabetes control in CKD. On the other hand, the low-protein intake increases the insulin-mediated glucose removal; indeed, in CKD patients the post-absorptive plasma levels of both glucose and insulin decreased after a very-low protein (high carbohydrates) diet supplemented with ketoacids, indicating the restoring of insulin sensitivity and the improving of glucose tolerance [28]. A possible mechanism has been suggested by a recent experimental study showing that the defective insulin secretion in CKD is related to the plasma urea level, demonstrating that circulating urea directly impairs insulin secretion by pancreatic islets [29].

In this study, around 80% of diabetic patient needed less insulin doses during LPD, but it is not known how many units were actually reduced; however, data on insulin use are not consistent to support the hypothesis of an improvement of insulin resistance with the LPD-KA. Despite that, the uric acid behaviour during the study allows to speculate on improvement of insulin resistance. After six months of low-protein diet, uric acid levels decreased in all patients with a final level similar between groups; it is plausible that uric acid drop during the short time period might be dependent on the low amount of purines in the LPD-KA diet. On the other hand, in the long term the uric acid markedly decreased in diabetics. Insulin resistance and uric acid are independently linked and there is strong epidemiological evidence that hyperuricemia may be either associated to or even predict the onset of insulin resistance [30, 31]. Formerly, hyperuricemia was considered as a consequence of insulin resistance due to the reduction of urinary uric acid excretion but later it was also suggested uric acid has a contributory causal role in diabetes [31, 32]. Indeed, insulin resistance in models of metabolic syndrome can be improved by lowering serum uric acid [33, 34]. Uric acid also blocks the insulin mediated endothelial nitric oxide release that is critical for insulin action [35]. The evidences of lowering uric acid on insulin resistance in human studies are limited. However, insulin resistance has been reported to be improved by urate lowering therapy; one study reported the improvement of glycated hemoglobin levels in diabetic subjects treated with allopurinol [36]. Therefore, in our CKD diabetic patients the low-protein diet directly lowered the uric acid level and, likely, the lower urea levels obtained with the LPD-KA improved the insulin resistance which further contributed to the lowering of uric acid. Overall, the reduction of uric acid improved the glucose metabolic profile most likely throughout amelioration of insulin resistance.

With respect the impact of low-protein diet on nutritional status, diabetic CKD patients in addition to insulin resistance, are more inflamed, have a worst control of metabolic acidosis; overall, this is an hyper-catabolic condition which can accelerate protein degradation and a reduced protein intake may not satisfy the nitrogen need to counterbalance the catabolic status [15]. At least theoretically, diabetic patients require more protein and aminoacids and a low-protein diet could expose the patient to higher risk of protein-energy wasting (PEW). Therefore, when prescribing a LPD in diabetics CKD, careful attention to adequate nutrient intake and to appropriate nutritional status is mandatory. In this study, all patients received a diet containing low proteins, around the minimum threshold for a neutral nitrogen balance and the diet was supplemented with essential aminoacids and ketoacids to reach the Recommended Dietary Allowance for proteins (0.8 g per kilo weight per day) for the adult population and considered the very minimum level for diabetics with CKD [37, 38]; a normal-high amount of calories was provided to be sure to fully cover the energy need. Besides, the dietary plan was personalized for each patient by a skilled dietitian who trained the patients at start and during the diet treatment and closely monitored the nutritional status.
Serum albumin was slightly lower in diabetics at baseline and did not change in both groups during the diet treatment. In contrast, body weight declined soon after the diet start and then remained stable even in the long-term follow-up; this is not unusual after the start of a low-protein diet. For instance, in the MDRD study which is one of the largest trial on low-protein diet in CKD, the weight suddenly declined during the first months of LPD irrespectively of either the CKD stage or the amount of protein prescription and thereafter remained stable during the follow-up [39]. In that study the energy intake was low in all the sub-groups during the LPD while the weight decline was observed only at start; if the low energy or proteins had an adverse impact on nutrition, it would be observed a similar decline up to the end of the study and, therefore, other factors contributed to the weight loss. A possible explanation is that in CKD the protein intake is strictly parallel to sodium intake [40]; in CKD, that is a salt-sensitivity condition, a sudden decline of sodium intake associated to the low-protein diet reduces the extracellular volume [41]. As a result, the sudden weight loss after LPD start may be due to water loss. In this study, the body weight decline at start was associated with a slight reduction of body water which can explain at least a portion of the weight loss.

A further change in body composition detected along the study was a small decline of fat mass. Fat free mass decreased by the same extent in both groups but such a decline may be attributed to the loss of body water; indeed, the fractional FFM did not reduce during the diet. Conversely, the muscle functionality evaluated by the hand-grip strength improved in DM but not non-DM during the follow-up on LPD-KA. Interestingly, sarcopenia defined by handgrip strength and skeletal muscle mass estimated by BIA has been shown as an independent predictor of mortality in CKD [42]; according to a threshold for hand-grip strength, in this study sarcopenia estimated by muscle strength was highly prevalent at baseline and slightly improved during the study [21].

Given the observational design of the study and the slight differences between groups at baseline, we cannot exclude that unmeasured confounders and diabetic status could have influenced the nutritional effect of LPD-KA diet. However, several multivariable analyses strongly suggest that diabetes seems not to play a role on the nutritional effects observed during the long-term observational study.

To obtain a comprehensive evaluation of PEW by the combination of several nutritional parameters, we analysed together one parameter for each of the main categories suggested by the International Society of Renal Nutrition and Metabolism [6]. Low levels of albumin and BMI were present in around one over three patients at start and this percentage did not change during the study; low cholesterol was absent in all patients at any time; prevalence of reduced fat mass was very low at start and did not worsen in both groups during the study period. Overall, the nutritional status and body composition according these combined criteria, did not worsen in diabetics CKD while on LPD-KA. Few data are available from literature. In a systematic review of randomised controlled trials, serum albumin did not worse in CKD diabetics during LPD; the heterogeneity between trials, however, was high [26]. In contrast, in a small controlled trial in diabetic patients, serum albumin decreased during LPD but not in control diet; patients on LPD, however, decreased the energy intake along the study [24]. Therefore, the adherence to energy prescription is mandatory to avoid a negative impact of LPD on nutrition in diabetic CKD. This latter point has been clearly underlined in recent nutritional recommendations for CKD [38].

Conclusion
This study provides first time evidence that in diabetic patient with advanced CKD a low-protein diet supplemented with ketoacids under a skilled dietitian supervision is safe. The major strengths of this study are that the nutritional status of the patients was comprehensively studied by a number of common either biochemical and clinical criteria or other tools for assessment of protein-energy wasting in CKD and that diabetic patients were compared along time with non-diabetics patients on the same intervention. A limitations of the study is that this is an observational but not randomized trial. Nonetheless, multivariate analyses does not disclose any association of diabetic status and main individual characteristics suggesting that the long-term effect of the low-protein diet is the same in diabetics and non-diabetics CKD patients. Therefore, the study concludes that a low-protein dietary supplemented with ketoacids reduces the accumulation of protein wasting products and ameliorates the glucose control improving the insulin sensitivity in diabetic CKD patients; furthermore, the study undoubtedly demonstrates that such restricted diet in the long term does not worsen the nutritional status and preserves the body composition avoiding the onset of sarcopenia in diabetic patients with CKD.

Abbreviations
ANOVA: Analysis Of Variance; BIA: Bioimpedance Analysis; BMI: Body Mass Index; BMR: Basal Metabolic Rate; BW: Body Weight; CKD: Chronic Kidney Disease; CKD-EPI: Chronic Kidney Disease Epidemiology; DBP: Diastolic Blood Pressure; DM: Diabetes Mellitus; eGFR: estimated Glomerular Filtration Rate; ESRD: End Stage Renal Disease; FFM: Fat-Free Mass; FM: Fat Mass; GFR: Glomerular Filtration Rate; IBW: Ideal Body Weight; KDIGO: kidney Disease Improving Global Outcomes; LPD: Low-Protein Diet; LPD-KA: Low-Protein Diet plus KetoAcids; LPDs: Low-Protein Diets; MDRD: Modification of Diet in Renal Disease; MFES: Mexican Food Equivalent System; non-DM: non- Diabetics Mellitus; NS: Non Significant; NYHA: New York Hart Association; PEW: Protein-Energy Wasting; SBP: Systolic Blood Pressure; SD: Standard Deviation; TBW: Total Body Water; W/H: Waist/Hip
Acknowledgements

Portions of this work have been presented as oral presentation at the 18th International congress on Nutrition and Metabolism in Renal Disease, Okinawa (Japan), 2016, and the 53rd International ERA-EDTA congress, Vienna (AU), 2016, as well as poster presentation at the Kidney Week of the American Society of Nephrology, Chicago (USA), 2016.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request at the following address: vincenzo.bellizzi@irin.it.

Authors’ contributions

VB conceived the study and wrote the manuscript; VB, PaC and ST designed of the study; JNH, VFG, SMl, RUA, RAWC conducted the clinical study and participated in its design; VB PaC and RM analysed the data; all authors gave a substantial contribution in the revision of the paper and approved the final manuscript.

Ethics approval and consent to participate

The research protocol was approved by the local ethical committee, the Ethics approval and consent to participate in the revision of the paper and approved the final manuscript.

Contributing in the study gave their informed consent to participate to the study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Division of Nephrology, Dialysis and Transplantation, University Hospital San Giovanni di Dio e Ruggi d’Aragona, Via San Leonardo, 84131 Salerno, Italy.
2Department of Movement and Wellness Sciences, University of Naples Parthenope, Naples, Italy.
3Centro de Atención Nutricional Fresenius Kabi, Ciudad de México, Mexico.
4Division of Nephrology, University Hospital Policlinico di Bari, Bari, Italy.
5Division of Nephrology, University of Campania, Luigi Vanvitelli, Napoli, Italy.

Received: 5 August 2017 Accepted: 2 May 2018

Published online: 09 May 2018

References

1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, Zhao MH, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–82. https://doi.org/10.1016/S0140-6736(14)61601-9.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):1483–508. https://doi.org/10.1016/S0140-6736(15)60128-0.

3. Kurella TM. Recognition for conservative Care in Kidney Failure. Am J Kidney Dis. 2016;68(5):673–6. https://doi.org/10.1053/j.jrn.2016.09.005.
4. Bellizzi V, Cupisti A, Locatelli F, Bolosco PG, Brunori G, Cancarini G, Garibotto G, Conti G, Minutolo R, santoro D, Torraca S, Viola BF, on behalf of the “Conservative Treatment of CKD” study group of the Italian Society of Nephrology. Low-protein diets for chronic kidney disease patients: the Italian experience. BMC Nephrol. 2016;17:177. https://doi.org/10.1186/s12882-016-0280-0.

5. Davison SN, Levin A, Moss AH, Jha V, Brown EA, Brennan F, Murtagh FE, Naicker S, Germain MJ, O’Donoghue DJ, Manton RL, Obrador GT. Kidney Disease: improving Global Outcomes executive summary of the KDIGO controversies conference on supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care. Kidney Int. 2015;88(3):447–59. https://doi.org/10.1038/ki.2015.110.

6. Fouque D, Kalantar-Zadeh K, Koppie JD, Cano N, Chauveau P, Cappuri L, Franch H, Guarnieri G, Kizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevinho-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Intern. 2008;73(4):391–8.

7. Monette FL, Laalain S, Shalib JK, Koppel JD. Energy expenditure in patients with chronic renal failure. Kidney Intern. 1986;30(5):741–7.

8. Cianciaruso B, Pota A, Pisani A, Torraca S, Anacchini R, Lombardi P, Capuano A, Nazzaro P, Bellizzi V, Sabbatini M. Metabolic effects of two low protein diets in chronic kidney disease stage 4–5—a randomized controlled trial. Nephrol Dial Transplant. 2008;23:636–44.

9. Cianciaruso B, Pota A, Bellizzi V, Di Giuseppe D, Di Micco L, Minutolo R, Pisani A, Sabbatini M, Ravani P. Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. Am J Kidney Dis. 2009;54(6):852–61.

10. D’Alessandro C, Piccoli GB, Calella P, Brunori G, Pistoric F, Bellizzi V, Cupisti A. “Dietaly”: practical issues for the nutritional management of CKD patients in Italy. BMC Nephrol. 2016;17(1):102. https://doi.org/10.1186/s12882-016-0296-5.

11. Aparicio M, Bellizzi V, Chauveau P, Cupisti A, Ecker T, Fouque D, Garneata L, Lin S, Mitchell WE, Tempel V, Yu X, Zakar G. Diet analogues still have a role in Delaying Dialysis initiation in CKD Predialysis Patients? Semin Dial. 2013;26:714–9.

12. Aparicio M, Bellizzi V, Chauveau P, Cupisti A, Ecker T, Fouque D, Garneata L, Lin S, Mitchell WE, Tempel V, Zakar G, Yu X. Protein-restricted diets plus ketone- amino acids - a valid therapeutic approach for chronic kidney disease patients. J Ren Nutr. 2012 Mar;22(2 Suppl):S1–21. https://doi.org/10.1016/j.jrn.2011.09.005.

13. Brunori G, Viola BF, Parrinello G, Di Bease V, Corso F, Garibotto G, Zubani R, Cancarini GC. Efficacy and safety of a very-low-protein diet when postponing Dialysis in the elderly: a prospective randomized multicenter controlled study. Am J Kidney Dis. 2007;49(5):560–80.

14. Alici AZ, Rooney MT, Tuttle RR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;13 https://doi.org/10.2215/CJN.11491116.

15. Gougeon R, Pencharz PB, Sigal RJ. Effect of glycemic control on the kinetics of whole-body protein metabolism in obese subjects with non-insulin-dependent diabetes mellitus during iso- and hyperenergetic feeding. Am J Clin Nutr. 1997;65(3):861–70.

16. Perez AB, Palacios B. Sistema Mexicano de Alimentos Equivalentes para Pacientes Renales. Mexico City: Ed. Fomento de Nutrición y Salud; 2009.

17. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new chronic kidney disease epidemiology collaboration equation in comparison with the modification of diet in renal disease equation study. Am Heart J. 2011;162(3):548–54.

18. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–63.

19. Di Iorio B, Terracciano V, Bellizzi V. Bioelectrical impedance measurement: errors and artifacts. J Renal Nutr. 1999:96(6):534–7.

20. Di Iorio B, Sciaffa L, Terracciano V, Bellizzi V A. Systematic evaluation of bioelectrical impedance measurement after the hemodialysis session. Kidney Int. 2004;65(S5):2435–40.

21. Bahat G, Tufan A, Tufan F, Kılç K, Akpinar TS, Kose M, Erten N, Karan MA, Cruz-Jentoff AJ. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clin Nutr. 2016;35(6):1557–63. https://doi.org/10.1016/j.clnu.2016.02.002.

22. Cianciaruso B, Capuano A, D’Amaro E, Ferrera N, Nastasi A, Conte G, Bellizzi V, Andreucci VE. Dietary compliance to a low protein and phosphate diet in patients with chronic renal failure. Kidney Intern. 1998;53(2):517–3.

23. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Santoro D, Sin-Canada R, Rome B. Dietary compliance to a low protein and phosphate diet on progression of CKD: follow-up of a randomized controlled trial. Am J Kidney Dis. 2016;68(5):673–6. https://doi.org/10.2215/CJN.11491116.

24. Meloni C, Morosetti M, Suraci C, Pennafina MG, Tozzo C, Tascone-Gallucci M, Casiciani CU. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr. 2002;12(2):96–101.

25. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Intern. 2002;62:220–8.

26. Nezu U, Kamiyama Y, Kondo Y, Sakuma M, Morimoto T, Ueda S. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ Open. 2013;3:e002934. https://doi.org/10.1136/bmjopen-2013-002934.
27. de Boer IH, Zelnick L, Afkarati M, Ayers E, Curtis L, Himmelfarb J, Ikizler TA, Kahn SE, Kestenbaum B, Utschneider K. Impaired glucose and insulin homeostasis in moderate-severe CKD. J Am Soc Nephrol. 2016;27(9):2861–71. https://doi.org/10.1681/ASN.2015070756.

28. Rigalleau V, Blancfaiet V, Combe C, Guillet C, Dellers G, Aubertin J, Aparicio M, Gin H. A low protein diet improves insulin sensitivity of endogenous production in pre-dialytic uremic patients. Am J Clin Nutr. 1997;65:5:1512–6.

29. Koppe L, Nyam E, Vivet K, Manning Fox J, Dai XQ, Nguyen BN, Trudel D, Attard C, Moulié VS, MacDonald PE, Ghilain J, Poitout V. Urea impairs β cell glycolysis and insulin secretation in chronic kidney disease. J Clin Invest. 2016;126(9):3598–612. https://doi.org/10.1172/JCI86181.

30. Avula NR, Sheny D. Evaluation of Association of Hyperuricaemia with metabolic syndrome and insulin resistance. J Clin Diagn Res. 2016;10(12):OC32–4.

31. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin Y, Lanapa MA. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62(10):3307–15.

32. Facchinetti F, Chen YD, Kolombeck CE, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3088–11.

33. Sanchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, Johnson RJ, Herrera-Acosta J. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens. 2006;15(1):30–3.

34. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin Y. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60(4):1258–69.

35. Nakagawa T, Hu H, Zhankvit S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625–31.

36. Dogan A, Yarliogluets M, Kaya MG, Karadag Z, Dogan S, Artic l, Dogdu O, Kilinc Y, Zencir C, Akpeh M, Ozdogru I, Ouyang A, Kaly N. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20(3):182–7.

37. Protein and aminoacid requirements in human nutrition. Report of a Joint FAO/WHO/UNU Expert Consultation. In: WHO Technical Report Series 935. 2007. http://www.who.int/nutrition/publications/nutrientrequirements/WHO_TRS_935/en/. Accessed 05 July 2018.

38. Bellizzi V, Bianchi S, Bolasco P, Brunori G, Cupisti A, Cambaro G, Gesualdo L, Polito P, Santoro D, Santoro A. Delphi consensus panel on nutritional therapy in chronic kidney disease. J Nephrol. 2016;29(5):593–602. https://doi.org/10.1007/s40620-016-0323-4.

39. Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Merril D, Scherch L, Wang S, Zimmer G. Effect of dietary protein restriction on nutritional status in the modification of diet in renal disease study: Modification of diet in renal disease study group. Kidney Int. 1997;52:778–91.

40. Cianciaruso B, Bellizzi V, Minuto R, Tavera A, Capuano A, Conte G, De Nicola L. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab. 1998;24(4):296–301.

41. Bellizzi V, Di Iorio BR, De Nicola L, Minuto R, Zamboli P, Trucillo P, Catapano F, Cristofaro C, Scaffa L, Conte G for the ERIKA Study-group. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int. 2007;71:245–51.

42. Pereira RA, Cordeiro AC, Avanesi CM, Carrero JJ, Lindholm B, Amparo FC, Ambeduc C, Cuppati L, Kamimura MA. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. Nephrol Dial Transplant. 2015 Oct;30(10):1718–25. https://doi.org/10.1093/ndt/gfv133.